Korea Otsuka Pharmaceutical Co., Ltd.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.otsuka.co.kr

Clinical Trials

Pletaal SR Post Marketing Observational Study

Completed

Conditions: Ischemic Symptoms
Cerebral Infarction

First Posted Date: 2013-02-04

Last Posted Date: 2019-03-01

Lead Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 3635

Registration Number: NCT01782833

Locations: 🇰🇷
Kyungpook National University Hospital, Daegu, Korea, Republic of
🇰🇷
Inje University Seoul Pail Hospital, Seoul, Korea, Republic of
🇰🇷
NHIC Ilsan Hospital, Goyang, Korea, Republic of

and more 1 locations

Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy

Phase 2

Completed

Conditions: Diabetic Nephropathy

Interventions: Drug: Probucol 250mg/day
Drug: Placebo
Drug: Probucol 500mg/day

First Posted Date: 2012-11-15

Last Posted Date: 2017-05-03

Lead Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 126

Registration Number: NCT01726816

Locations: 🇰🇷
Kyungpook National University, DaeGu, Korea, Republic of
🇰🇷
The Catholic university of Korea, Bucheon St. Mary's Hospital, Bucheon, Korea, Republic of
🇰🇷
Gil Hospital, Incheon, Korea, Republic of

and more 13 locations

A Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to Chronic Occlusive Arterial Disease

Phase 4

Completed

Conditions: Chronic Occlusive Arterial Disease

Interventions: Drug: Pletaal SR capsule

First Posted Date: 2012-10-22

Last Posted Date: 2022-06-10

Lead Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 101

Registration Number: NCT01711333

Locations: 🇰🇷
KYUNG-HEE UNIVERSITY HOSPITAL at GANGDONG, Seoul, Korea, Republic of

Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites

Phase 4

Terminated

Conditions: Hyponatremia and Extracellular Fluid in Cirrhotic

Interventions: Drug: Tolvaptan
Drug: Placebo

First Posted Date: 2012-03-13

Last Posted Date: 2022-03-04

Lead Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 74

Registration Number: NCT01552590

Locations: 🇰🇷
Soonchunhyang Univ. Bucheon Hospital, Bucheon, Korea, Republic of
🇰🇷
Hallym Univ. Chuncheon Sacred Heart Hospital, Bucheon, Korea, Republic of
🇰🇷
Wonju Christian Hospital, Wonju, Korea, Republic of

Evaluate the Efficacy and Safety of Pletaal (Cilostazol) in Subjects With Vasospastic Angina

Phase 2

Completed

Conditions: Variant Angina

Interventions: Drug: Placebo

First Posted Date: 2011-10-03

Last Posted Date: 2012-07-16

Lead Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 50

Registration Number: NCT01444885

Locations: 🇰🇷
Ajou University Hospital, Suwon, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
ChungNam Univ. Hospital, DaeJeon, Korea, Republic of

and more 7 locations

Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Certolizumab Pegol

First Posted Date: 2010-09-09

Last Posted Date: 2022-06-10

Lead Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 110

Registration Number: NCT01197066

Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety

Phase 2

Completed

Conditions: Peripheral Artery Disease

Interventions: Drug: Cilostazol, Probucol

First Posted Date: 2010-06-11

Last Posted Date: 2022-07-18

Lead Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 80

Registration Number: NCT01142284

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Pharmacokinetics/Pharmacodynamics (PK/PD) Characteristics of Tolvaptan Tablet in Korean Healthy Male

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tolvaptan 15mg or 30mg or 60mg or Placebo

First Posted Date: 2009-11-17

Last Posted Date: 2010-03-11

Lead Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 46

Registration Number: NCT01014416

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Pharmacokinetics Study for Probucol

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: probucol

First Posted Date: 2009-10-23

Last Posted Date: 2022-03-04

Lead Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT01000467

Locations: 🇰🇷
Seoul national univeristy, Seoul, Korea, Republic of

A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo of CDP870
Drug: CDP870 200mg
Drug: Methotrexate

First Posted Date: 2009-10-12

Last Posted Date: 2012-09-27

Lead Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 127

Registration Number: NCT00993317

Locations: 🇰🇷
Seoul national univeristy, Seoul, Korea, Republic of
🇰🇷
Catholic University of Korea ST.Mary's Hospital, Seoul, Korea, Republic of
🇰🇷
Catholic University Hospital of Daegu, Daegu, Korea, Republic of

and more 12 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy